First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

AIMS: Human genetic, tissue expression, proteomics, transcriptomics and nonclinical studies implicate tumour necrosis factor α‐like ligand 1A (TL1A) as a novel target in inflammatory bowel disease (IBD). PF‐06480605, a fully human immunoglobulin G1 monoclonal antibody, targets TL1A. This first‐in‐hu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Clin Pharmacol
Hauptverfasser: Banfield, Christopher, Rudin, Dan, Bhattacharya, Indranil, Goteti, Kosalaram, Li, Gang, Hassan‐Zahraee, Mina, Brown, Lisa S., Hung, Kenneth E., Pawlak, Sylvester, Lepsy, Christopher
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2020
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098865/
https://ncbi.nlm.nih.gov/pubmed/31758576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14187
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge